Table 2.
Association between βIII-tubulin expression and clinico-pathologic parameters.
| Patients with no TUBB3 expression n=215 | Patients with TUBB3 expression n=43 | Univariate analysis | ||
|---|---|---|---|---|
| p | OR [95%CI] | |||
| Age, No (%): | ||||
| <65 years | 105 (48.8) | 19 (44.2) | 0.577 | |
| >65 years | 110 (51.2) | 24 (55.8) | ||
| Age, years (mean) | 64.6 | 63.8 | 0.399 | |
| Clinical stage, No (%): | ||||
| T1 | 151 (70.2) | 25 (58.2) | 0.068 | |
| T2 or more | 64 (29.8) | 18 (41.9) | ||
| PSA, No (%): | ||||
| <10 ng/ml | 119 (55.3) | 19 (44.2) | 0.180 | |
| >10 ng/ml | 96 (44.7) | 24 (55.8) | ||
| PSA, ng/ml (mean) | 13.1 | 19.5 | 0.066 | |
| Gleason score, No (%): | ||||
| ≤7 | 172 (80.0) | 24 (55.8) | 0.001 | 3.17 [1.59–6.30] |
| ≥8 | 43 (20.0) | 19 (44.2) | ||
| Primary Gleason grade 4 or 5, No (%): | 72 (33.5) | 23 (53.5) | 0.013 | 2.28 [1.18–4.43] |
| Prostate weight, No (%): | ||||
| <50 gr | 88 (40.9) | 22 (51.2) | 0.264 | |
| >50 gr | 127 (59.1) | 21 (48.9) | ||
| Prostate weight, gr (mean) | 55.9 | 54.2 | 0.724 | |
| pT stage, No (%): | ||||
| pT2 | 131 (60.9) | 19 (44.2) | 0.042 | 1.97 [1.02–3.82] |
| pT3-4 | 84 (39.1) | 24 (55.8) | ||
| Extracapsular extension, No (%): | 74 (34.4) | 22 (51.2) | 0.028 | 2.10 [1.08–4.09] |
| Positive surgical margins, No (%): | 43 (20.0) | 13 (30.2) | 0.116 | |
| Seminal vesicle invasion, No (%): | 42 (19.5) | 14 (32.6) | 0.059 | |
| Positive lymph nodes, No (%): | 15 (7.0) | 8 (18.6) | 0.034 | 3.05 [1.20–7.73] |
| Recurrence, No (%): | 46 (21.4) | 16 (37.2) | 0.029 | 2.15 [1.07–4.33] |
| Duration of follow-up, months (mean) | 62.1 | 58.4 | 0.603 | |
Clinical data, pathologic features, PSA failure: correlations with βIII-tubulin expression in HNPC samples (univariate analysis). HNPC: hormone naive prostate cancer; PSA: prostate specific antigen.